HealthQuest Capital’s Post

Top 25 Healthcare Investors in 2024. What a list to be a part of! Rami El Assal gave me an opportunity to bring my skillset to bear in his due diligence team, and along the way built with managing partners Stephen Thaddeus Connelly and Ryan Spitler, Ph.D. a Top 25 venture fund. For anyone out there looking to expand their skill set, I encourage you to take that leap of faith and aggressively pursue those opportunities that will get you to where you want to achieve in your professional career. Boutique was a fit for me because: - They had great deal flow and brought creativity to deals that allowed great deals to get done where conventional thinking wouldn't work - Deep scientific expertise. I get to learn about cutting-edge technology on a diligence team that writes academic books on the topics they invest in. - Their long-term support with investments gives me a front-row seat to witness companies and their founders grow into professional entrepreneurs and successful businesses - The people of Boutique have the right kind of ego. They know what they know, cold. They learn what they need to learn. Their approach has created opportunities for me to work with other prestigious venture firms because they benefit from Boutique's domain and deal expertise without the attitude. So, definitely make your list. Knock on doors... and don't take no for an answer. Even without a Top 25 nomination, supporting Boutique has continued to be a world-class experience. Many thanks to Boutique for this opportunity and my co-conspirator Craig Rochester for the pearls of wisdom he drops on our due diligence calls. #intellectualproperty #venturecapital

This table contains the most active investors currently competing in kidney related health care innovation across their respective company lifecycle. The group broadly represents four investor types that provide this timeline to consider performance stage indicators starting from early initial idea implementation to accerated performance indicators, capital restructuring, credit acquisitions to a finalized IPO: (a) accelerators; (b) early stage venture capital; (c) growth equity; and (d) strategic capital. #unitedseniorassociation #usa #advocate #safeservicesolutions #recoveredreflections #healthcare #technology #ditigalhealth #CMS #kloekorby #nyclifestyleinfluencer #leadership #community #initiative #seniorcare #sustainable #united #innovation #development #HHS #humanity #eldercare #NYC #linkedinforcreators #patientcare

Insight Partners has invested in Employer Direct Healthcare at a $1 billion valuation, via a secondary transaction. John Zutter, CEO of EDH, said, “…this investment provides an attractive outcome for some of our earliest backers, including TEXO Ventures.” Scott Barclay of Insight Partners said, “EDH is a rare example of the right management team, the right model, and the right technology to truly change the outcomes and business of healthcare.” #Secondaries #Secondary #SecondaryMarket #AlternativeInvestments #PrivateMarkets #Deals #InstitutionalInvestors #Valuation #Investing #Venture #VentureCapital #VC #Technology #VentureFunding #HealthTech #Healthcare #Health #HealthcareInnovation https://lnkd.in/eUznMzQ7

This is a snapshot of the current attractive industries and sub-verticals in the private direct investment landscape

"What Private Wants and What #HealthInnovation Ventures Must Show." FINN Chair Global Health and Purpose Gil Bashe presents at HITLAB. Gil underscores why too many people are focused on PE money ups and downs instead of where the money is focused and why. He taps into the Galen Growth | Insights You Can Trust data. It's the navigational guide for business development and venture capital. WATCH: https://lnkd.in/guhUBqXf

Dan Angius, Managing Director at Nasdaq, joined Inning 8: Exits: M&A & IPO, hosted by Christiaan Engstrom, founder and CEO of the Bullpen. "It seems as though the window for biotech has opened ahead of other sectors, including general healthcare. Why is that important? Well, actually, historically, when you see periods of IPO drought, one of the first catalysts that happened is that the healthcare market, specifically the biotech markets, are the first ones to wake up when we're coming out of the drought, because generally speaking, they're somewhat detached from overall market gyrations by virtue of science and phase results. We've been seeing that." View here: https://lnkd.in/gzTxXxf5 Each week leading up to BIO 2024 in San Diego, the Bullpen holds a virtual meeting (#BullpenInnings) featuring 10+ industry leaders. Keep up to date on the status of the market in the Bullpen and join us for Inning 9: Pitch Competition (May 29th, 2024 | 12-1PM ET), exclusive to Bullpen members only. Become a Member: https://lnkd.in/gKhx6SHN The #Bullpen is an invite-only, volunteer-led Club that gathers Life Science Investors and CxOs with a shared goal of helping each other. Our Mantra: Find someone to help. Repeat. https://lnkd.in/gN7rvyZP Interested in becoming a Club Member? Schedule a brief intro meeting with Bullpen Member Director Laura Farley, CRPC here: https://lnkd.in/gRNaBF85 Nola E. Masterson, Portfolia Femtech Funds, Vered Gigi, PhD, aMoon Fund, Dan Angius, Nasdaq, David H. Crean, Cardiff Advisory LLC, Anne DeGheest, HealthTech Capital, Susan Grant Schneider, MPS, Sequoia Biotech Consulting, Chris Mayo, CFA, LSEG (London Stock Exchange Group), Keara S., Sauber Capital, Andy Danielsen, Mayo Clinic, Jeff Steinle, Fredrikson & Byron, P.A.

When it comes to the valuation of joint ventures and leased facilities in the health care space, there are many challenges inherent in deriving valuation metrics from comparable public companies or M&A transactions. While the recent IPO of Ardent Health (ARDT) showcases the company’s unique attributes, it does also complicate attempts at using ARDT for comparability studies. https://lnkd.in/ehbxymrs

Altaris, LLC, a private equity firm, agreed to acquire Sharecare, a digital health company, for $540m. “Today’s announcement not only delivers value for Sharecare’s stockholders but also will result in exciting opportunities for our employees and customers. This transaction is an important step forward to enable the continued growth and evolution of Sharecare, and further strengthens us as we deploy our innovative technology across the healthcare sector," Brent Layton, Sharecare CEO. Sharecare (led by Brent Layton, Jeff Arnold, Justin Ferrero and Carrie Ratliff) is advised by Houlihan Lokey, MTS Health Partners, King & Spalding, and Wachtell, Lipton, Rosen & Katz (led by Dan Neff, Mark Gordon and Meng Lu). Altaris, LLC (led by Daniel Tully, George Aitken-Davies, Lana Dweik and Chuck Mullens) is advised by Kirkland & Ellis. #MergersAcquisitionsDivestitures #PrivateEquity #HealthCare #Technology

Read the MedTech Strategies LLC article below about our most recent event on healthcare's current (and future) financing trends. Don't miss Gabriele Brambilla's suggestions for the new year: 1) Watch for microeconomic trends to see what might affect your pathway. 2) Be creative and use different channels to develop relationships and adjust your approach. 3) Focus on clinical evidence and patient impact that might come through a clinical pathway other than 510k. 4) And of course, never give up!

🎉 Celebrating the Most Impactful Digital Health Investors in European Early-Stage Ventures At Galen Growth | Insights You Can Trust, we have developed a comprehensive methodology to identify the most impactful #digitalhealth investors worldwide. In other words, investors who have invested at least once each year from 2019 to 2023 inclusive. It is important to note that our analysis excludes all forms of public funding. The top 5 investors by total raise of their European Early-Stage investees are: Khosla Ventures Elaia Speedinvest Octopus Ventures Hoxton Ventures Congratulations to these investors committed to Digital Health innovation, whatever the funding and valuation climate. Each investor's detailed portfolio of investments in Digital Health can be viewed at www.healthtechalpha.com #ht24 #investment #europe